Dr. Patel is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
5323 Harry Hines Boulevard
Dallas, TX 75390Phone+1 214-645-4673Fax+1 214-645-2661
Education & Training
- University of Texas Southwestern Medical CenterFellowship, Hematology and Medical Oncology, 2008 - 2011
- Washington University/B-JH/SLCH ConsortiumResidency, Internal Medicine, 2005 - 2008
- Creighton University School of MedicineClass of 2005
Certifications & Licensure
- TX State Medical License 2009 - 2024
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013
Clinical Trials
- Myelodysplastic Syndromes (MDS) Event Free Survival With Iron Chelation Therapy Study Start of enrollment: 2010 Mar 22
- Safety and Efficacy Study of Pracinostat With Azacitadine in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia (AML) Start of enrollment: 2013 Dec 24
- Phase 2 Study Adding Pracinostat to a Hypomethylating Agent (HMA) in Patients With MDS Who Failed to Respond to Single Agent HMA Start of enrollment: 2013 Dec 01
- Join now to see all
Publications & Presentations
PubMed
- 39 citationsA Phase Ib Study of Onvansertib, a Novel Oral PLK1 Inhibitor, in Combination Therapy for Patients with Relapsed or Refractory Acute Myeloid LeukemiaAmer M. Zeidan, Maya Ridinger, Tara L. Lin, Pamela S. Becker, Gary J. Schiller
Clinical Cancer Research. 2020-09-30 - 25 citationsA Clinical Phase 1B Study of the CD3xCD123 Bispecific Antibody APVO436 in Patients with Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome.Fatih M. Uckun, Tara L. Lin, Alice S. Mims, Prapti Patel, Cynthia Lee
Cancers. 2021-08-15 - 125 citationsIvosidenib or enasidenib combined with intensive chemotherapy in patients with newly diagnosed AML: a phase 1 studyEytan M. Stein, Courtney D. DiNardo, Amir T. Fathi, Alice S. Mims, Keith W. Pratz
Blood. 2021-04-01
Abstracts/Posters
- Precision Medicine Treatment in Older AML: Results of Beat AML Master TrialClinically Relevant AbstractPrapti A. Patel, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Prevalence of Inherited Cancer Predisposition Mutations in a Cohort of Older AML Patients Enrolled on the Beat AML Master TrialPrapti A. Patel, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Pharmacokinetic Exposure Equivalence and Preliminary Efficacy and Safety from a Randomized Cross over Phase 3 Study (ASCERTAIN study) of an Oral Hypomethylating Agent ...Prapti A. Patel, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Join now to see all
Press Mentions
- Dr. Patel on the Role of Gilteritinib in FLT3+ AMLFebruary 17th, 2020
- Targeted Therapy Shifts AML Paradigm, but More Work Lies AheadJanuary 28th, 2020
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: